iCAD, Inc. (ICAD)
NASDAQ: ICAD · IEX Real-Time Price · USD
1.530
+0.010 (0.66%)
Apr 23, 2024, 1:36 PM EDT - Market open

Company Description

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States.

It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.

The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

iCAD, Inc.
iCAD, Inc. logo
Country United States
Founded 1984
IPO Date Dec 3, 1986
Industry Medical Devices
Sector Healthcare
Employees 67
CEO Ms. Dana R. Brown

Contact Details

Address:
98 Spit Brook Road, Suite 100
Nashua, New Hampshire 03062
United States
Phone 603-882-5200
Website icadmed.com

Stock Details

Ticker Symbol ICAD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000749660
CUSIP Number 44934S206
ISIN Number US44934S2068
Employer ID 02-0377419
SIC Code 3841

Key Executives

Name Position
Dana R. Brown President, Chief Executive Officer and Executive Chair
Jonathan Go Chief Technology Officer
Eric Lonnqvist Chief Financial Officer
Michelle Strong Chief Operations Officer
Annette L. Heroux Vice President of Administration
Anthony Takazawa Director of Investor Relations
Brian Testa Chief People Officer
Bill Keyes Senior Vice President of Global Sales Operations
Vasu Avadhanula Chief Product Officer
Peter Graham Senior Vice President of North American Sales

Latest SEC Filings

Date Type Title
Mar 29, 2024 10-K Annual Report
Mar 12, 2024 8-K Current Report
Feb 26, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 25, 2024 8-K Current Report
Dec 28, 2023 144 Filing
Nov 14, 2023 10-Q Quarterly Report
Nov 13, 2023 8-K Current Report
Nov 7, 2023 8-K Current Report
Oct 23, 2023 8-K Current Report